Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Breast 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Other 1Genitourinary 1Gastrointestinal 1

Conditions

Non-alcoholic Fatty Liver Disease 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 765Gemcitabine 651Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 441Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 218pembrolizumab 206Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 181Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lisinopril × Gastrointestinal × Clear all
NCT04550481 2026-01-21

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Northwestern University

Phase 2 Active not recruiting
45 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡